Chlorophyllipt

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT CHLOROPHYLLIPT

Composition:

Active substance: 1 tablet contains 12.5 mg or 25 mg of chlorophyllipt extract, dry (10.76:1) (extractant ethanol 93%);

Excipients: sugar, ascorbic acid, calcium stearate.

Pharmaceutical form. Tablets.

Main physicochemical characteristics: tablets ranging from light green to green in color with specks, flat cylindrical in shape, with a score line and bevel, with a specific odor.

Pharmacotherapeutic group. Preparations used for throat disorders. Antiseptics. ATC code R02A A20.

Pharmacological Properties

Pharmacodynamics

Chlorophyllipt is a mixture of chlorophylls derived from eucalyptus leaves. The drug exerts antibacterial (bacteriostatic and bactericidal) effects against staphylococci, as well as antiseptic and anti-inflammatory actions.

Pharmacokinetics

Not studied.

Clinical characteristics.

Indications. Upper respiratory tract diseases (tonsillitis, pharyngitis, laryngitis), as well as aphthous and ulcerative stomatitis.

Contraindications. Hypersensitivity to chlorophyllipt or to other components of the drug.

Interaction with other medicinal products and other forms of interaction. Enhances the effect of antiseptic agents.

Special precautions.

Before starting use, consult a physician.

After the first application, a pause of 6–8 hours should be made. Continuous treatment with the drug is possible only after confirming the absence of an allergic reaction to the thick chlorophyllipt extract (possible lip swelling, nasal mucosa, pharynx, and other allergic reactions). If any of the above symptoms occur, discontinue use of the drug and consult a physician.

If a patient has known intolerance to certain sugars, medical advice should be sought before taking this medicinal product.

Use during pregnancy or breastfeeding. The efficacy and safety of the drug during pregnancy or breastfeeding have not been studied; therefore, the drug should not be used in these patient groups.

Ability to affect reaction rate while driving or operating machinery. Not studied.

Method of administration and dosage.

Administer tablets of 12.5 mg or 25 mg to adults, depending on the severity of the pathological condition. The tablets should not be swallowed or chewed, but held in the mouth until completely dissolved. The daily dose for adults is 25 mg five times a day. Dosage schedule: 1 tablet (12.5 mg or 25 mg) every 4–5 hours. Treatment duration: 7 days.

Children. There is no experience with the use of the drug in children.

Overdose. May result in an increase in adverse reactions.

Adverse reactions.

Allergic reactions, including rash, itching, angioedema, hyperemia.

Gastrointestinal tract: irritation of the oral mucosa, nausea, vomiting.

Nervous system: headache, dizziness.

Shelf life. 3 years.

Storage conditions. Store at a temperature not exceeding 25 °C in the original packaging.

Keep out of the reach of children.

Packaging. Tablets 12.5 mg № 20, № 10x2 in blisters in a carton; tablets 25 mg № 40 in containers, № 20, № 10x2 in blisters in a carton.

Availability category. Over-the-counter.

Manufacturer.

Limited Liability Company "Research Plant "GNCLC".

LIMITED LIABILITY COMPANY "CORPORATION "ZDOROVIYA".

Manufacturer's location and address of business activity.

Ukraine, 61057, Kharkiv region, city of Kharkiv, Vorobiova street, building 8.

(Limited Liability Company "Research Plant "GNCLC")

Ukraine, 61013, Kharkiv region, city of Kharkiv, Shevchenka street, building 22.

(LIMITED LIABILITY COMPANY "CORPORATION "ZDOROVIYA")